Skip to main content
An official website of the United States government

gefitinib

View Patient Information
An anilinoquinazoline with antineoplastic activity. Gefitinib inhibits the catalytic activity of numerous tyrosine kinases including the epidermal growth factor receptor (EGFR), which may result in inhibition of tyrosine kinase-dependent tumor growth. Specifically, this agent competes with the binding of ATP to the tyrosine kinase domain of EGFR, thereby inhibiting receptor autophosphorylation and resulting in inhibition of signal transduction. Gefitinib may also induce cell cycle arrest and inhibit angiogenesis.
US brand name:Iressa
Code name:ZD 1839
Chemical structure:4-(3chloro-4-flurophenylamine)-7-methoxy-6(3-(4morpholinyl)quinazoline
4-quinazolinamine, N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-4-morpholin] propoxy]
N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) propoxy]-4-quinazolinamine
IND number:61187
NSC code:715055
Search NCI's Drug Dictionary